PT-141 Nasal Spray vs Injection: Forms, Evidence, and Legality

PT-141 (bremelanotide) is available as a subcutaneous injection and, in compounded form, as a nasal spray. Only the injectable product, Vyleesi, is FDA-approved, and only for premenopausal women with hypoactive sexual desire disorder. Compounded PT-141 nasal spray is off-label, not FDA-approved, and supported by less rigorous evidence. Which form, if any, is appropriate is a licensed provider’s decision. This article is educational and not medical advice; PT-141 is prescription-only.

What PT-141 is and how it works

PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide and a melanocortin receptor agonist. It activates melanocortin receptors in the central nervous system, primarily MC4R and also MC3R, within the hypothalamus. Through those receptors it is thought to influence dopamine and oxytocin signaling, pathways involved in sexual desire and arousal.

This central mechanism is what sets PT-141 apart from PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis). Those medications act peripherally, on blood flow to genital tissue. PT-141 instead acts in the brain, on the neural circuits associated with desire itself. Because it is prescription-only, a licensed provider evaluates whether it is appropriate before any form is considered.

The two forms: injection and nasal spray

The FDA-approved product, Vyleesi, is delivered as a subcutaneous injection using a prefilled autoinjector. In the approved regimen it is self-administered into the abdomen or thigh. Beyond the branded product, licensed compounding pharmacies may prepare bremelanotide as a compounded preparation. Compounded PT-141 can be dispensed as a subcutaneous injection or, off-label, as a nasal spray.

The nasal spray form is not the FDA-approved product. It is a compounded, off-label preparation, and the published evidence for it is less rigorous than the trial data that supported the injectable. The table below compares the two routes on regulatory status, evidence, administration, and timing.

Характеристика	Подкожная инъекция	Nasal spray
Статус FDA	FDA-approved as Vyleesi (2019) for premenopausal women with HSDD only; compounded injectable use in men or for ED is off-label	Not FDA-approved in any form; compounded and off-label only
Доказательная база	Phase 3 RECONNECT trials in women; earlier investigational studies in men	Less rigorous; no comparable phase 3 program for the nasal route
Способ применения	Autoinjector into the abdomen or thigh (per Vyleesi labeling)	Sprayed into the nasal passages; technique-dependent
Absorption	Delivers a measured dose beneath the skin	Absorbed across nasal mucosa; more variable
Onset and timing	Vyleesi is used at least 45 minutes before anticipated activity	Not standardized by the FDA; onset is less predictable

Что показывают данные

Women and HSDD

The strongest evidence for bremelanotide comes from the RECONNECT phase 3 trials in premenopausal women with acquired, generalized HSDD. In that program, Vyleesi improved measures of sexual desire and reduced the distress associated with low desire compared with placebo. These are the findings that supported the 2019 FDA approval, and they apply to the subcutaneous injectable product in that specific population.

Men and erectile function (investigational)

Earlier bremelanotide research included studies in men, among them a subset of men who had not responded to sildenafil, and reported improvements in erectile response. However, bremelanotide is not FDA-approved for men or for erectile dysfunction, and these earlier findings do not establish approved efficacy. Any use in men should be understood as investigational and off-label. The nasal spray specifically has less rigorous evidence than the injectable, so results reported for one form and route do not automatically transfer to the other.

FDA and 503A regulatory status

The regulatory picture is important and often misunderstood. Bremelanotide is FDA-approved only as Vyleesi, approved on June 21, 2019, and only for premenopausal women with acquired, generalized HSDD. It is not FDA-approved for men or for erectile dysfunction. Any use in men, and any compounded PT-141 (including a nasal spray), is off-label and not FDA-approved.

Compounded PT-141 is prepared by licensed pharmacies under section 503A of the Federal Food, Drug, and Cosmetic Act. It is prescription-only. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before they reach patients. That does not make compounding inappropriate, but it does mean the oversight is different from an FDA-approved product, and it is one reason the form is a provider decision rather than a self-directed one.

Absorption: why the form matters

A subcutaneous injection deposits a measured amount of medication beneath the skin, which gives relatively predictable absorption. A nasal spray relies on the drug crossing the mucous membranes inside the nose. That route is inherently more variable: mucus, congestion, allergies, and spray technique can all affect how much is absorbed and how quickly. Because the nasal form has not been through the same rigorous, standardized testing as the injectable, its dose-to-effect relationship and onset are not established by the FDA. A provider weighs these differences when deciding whether any form fits a given person.

Safety and side effects

In clinical trials of bremelanotide, the most common adverse effects were nausea (reported by roughly 40 percent of participants), flushing (about 20 percent), headache (about 11 percent), and injection-site reactions. Bremelanotide also causes transient increases in blood pressure, on the order of 6 mmHg systolic and 3 mmHg diastolic, along with decreases in heart rate for several hours after a dose. For that reason it is not recommended for people with uncontrolled hypertension or known cardiovascular disease.

With repeated use, and more likely with daily dosing, focal hyperpigmentation (darkening of the skin, face, or gums) can occur. Because PT-141 is prescription-only, a licensed provider screens for these contraindications and monitors use. Side-effect profiles observed in trials were tied to the studied product and route; a compounded nasal spray has not been characterized to the same standard.

Who is a candidate

PT-141 is not a first-line, over-the-counter option and it is not right for everyone. Candidacy is determined individually by a licensed provider who reviews your health history, current medications, blood pressure, and cardiovascular status. People with uncontrolled hypertension or known cardiovascular disease are generally not appropriate candidates. The purpose of that evaluation is to match any treatment, and any form of it, to the person rather than the other way around.

Как к этому подходит Revive

Revive Longevity is prescription-only and provider-led. Where Revive dispenses PT-141, it is a compounded preparation from a licensed pharmacy, not the branded Vyleesi, and it is used off-label only where a licensed provider determines it is appropriate. It is not FDA-approved, and the provider determines eligibility after screening.

Importantly, the form of any treatment, including whether an injection or another route is used, is a clinical decision made by the provider, not a menu item selected by the patient. If you want to understand the process, our how Revive works page walks through the provider-led steps from intake to follow-up.

Часто задаваемые вопросы

Is PT-141 nasal spray FDA-approved?

No. The only FDA-approved form of bremelanotide is Vyleesi, a subcutaneous injection approved in 2019 for premenopausal women with HSDD. A PT-141 nasal spray is a compounded, off-label preparation and is not FDA-approved.

Is the nasal spray as effective as the injection?

The evidence for the nasal spray is less rigorous. The strongest, phase 3 trial data are for the subcutaneous injectable. Findings for one form and route do not automatically transfer to another, so effectiveness of the nasal form is not established to the same standard.

How is PT-141 different from Viagra?

PT-141 works centrally, activating melanocortin receptors in the brain to influence sexual desire. PDE5 inhibitors such as Viagra work peripherally, on blood flow to genital tissue. They target different steps and are not interchangeable.

Can men use PT-141?

Bremelanotide is not FDA-approved for men or for erectile dysfunction. Earlier studies in men reported some improvement in erectile response, but that use is off-label and investigational. A licensed provider decides whether it is appropriate.

What are the main side effects?

The most common effects in trials were nausea, flushing, headache, and injection-site reactions. Bremelanotide also causes transient increases in blood pressure and is not recommended for people with uncontrolled hypertension or known cardiovascular disease.

Who decides which form I receive?

A licensed provider does. The choice of form, including whether an injection or another route is used, is a clinical decision based on your health history and screening, not something selected without medical supervision.